Answers are grounded in this paper and cite their sources.
Systematic review reveals sotatercept improves outcomes in pulmonary arterial hypertension, suggesting enhanced treatment options.
Background Pulmonary arterial hypertension (PAH) is a progressive condition that leads to right ventricular failure and reduced survival. Sotatercept, a fusion protein targeting the activin signaling pathway, may offer disease-modifying benefits.
No takes yet. Share an insight, caveat, or question.
Manasrah et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: